Federal Circuit Urged to Preserve Novartis’ Bench Trial Loss
By Editorial Team
MSN Pharmaceuticals has pushed back against Novartis’ efforts to save its case accusing the generic-drug maker of infringing a patent covering the blockbuster cardiovascular drug Entresto. The appeal filed by Novartis has been challenged by MSN Pharmaceuticals, stating that it “reveals no district court error, just Novartis’ poor litigation strategy.”
Novartis’ appeal to the Federal Circuit seeks to overturn a bench trial loss in the patent infringement case. The case revolves around a patent covering the drug Entresto, a significant product in Novartis’ pharmaceutical portfolio.
The legal battle between Novartis and MSN Pharmaceuticals has attracted attention due to the implications it may have on the pharmaceutical industry and patent rights. The outcome of this case could set a precedent for future patent disputes within the industry.
Law360 subscribers have access to detailed information about the case, including court documents, briefs, and related sections such as appellate law, intellectual property, and trials. The case has been closely followed by legal analysts and industry experts, anticipating the Federal Circuit’s decision on whether to preserve Novartis’ bench trial loss.
Legal experts from law firms including Daignault Iyer, Morrison & Foerster, Rakoczy Molino, and Venable LLP have been involved in representing the parties in this high-stakes patent dispute. The case has been under the jurisdiction of the U.S. Court of Appeals for the Federal Circuit.
The patent in question, numbered 11,096,918, pertains to the amorphous solid form of compounds containing specific chemical moieties related to the drug Entresto. The case has been overseen by Judge Richard G. Andrews.
The decision by the Federal Circuit on whether to preserve Novartis’ bench trial loss will have far-reaching implications for both Novartis and MSN Pharmaceuticals, as well as the broader pharmaceutical industry. The outcome of this appeal could shape future patent litigation strategies and the enforcement of intellectual property rights in the sector.
